Figure S5. Trametinib Overcomes Dasatinib Resistance in a Flank model of thyroid tumorigenesis. from The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer
Authors:
- Thomas C. BeadnellTBThomas C. Beadnell
- Katie M. MishallKMKatie M. Mishall
- Qiong ZhouQZQiong Zhou
- Stephen M. RiffertSRStephen M. Riffert
- Kelsey E. WuenschKWKelsey E. Wuensch
- Brittelle E. KesslerBKBrittelle E. Kessler
- Maia L. CorpuzMCMaia L. Corpuz
- Xia JingXJXia Jing
- Jihye KimJKJihye Kim
- Guoliang WangGWGuoliang Wang
- Aik Choon TanATAik Choon Tan
- Rebecca E. SchweppeRSRebecca E. Schweppe
Open Access
- 3 April 2023
- other
- Published by American Association for Cancer Research (AACR)